Rona Yaeger, MD

Assistant Attending Physician, Department of Medicine

Rona Yaeger

Lab Phone


My research studies the role of growth and survival signaling pathways in colorectal cancer, focusing on the effects of selective therapeutics against nodes in these pathways. I am interested in the dysregulation of mitogen-activated protein kinase (MAPK) signaling that commonly occurs in colorectal cancer, resulting from epidermal growth factor receptor (EGFR) activation or activating mutations in RAS or RAF, and the consequences of this dysregulation on parallel and downstream signaling. A representative work is a Nature paper describing the emergence of KRAS mutations with acquired resistance to EGFR targeting agents. As an assistant attending physician I am interested in using this understanding to guide the selection of patient populations whose tumors are likely to respond to MAPK or PI3K (phosphatidylinositol 3-kinase) pathway inhibitors, and to suggest rational therapeutic combinations to enhance the antitumor effect of these agents.